{"id":6685,"date":"2024-11-21T16:01:25","date_gmt":"2024-11-21T15:01:25","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=publication&p=6685"},"modified":"2025-04-28T22:08:34","modified_gmt":"2025-04-28T20:08:34","slug":"tislelizumab-versus-sorafenib-in-first-line-treatment-of-unresectable-hepatocellular-carcinoma-impact-on-health-related-quality-of-life-in-rationale-301-study","status":"publish","type":"publication","link":"https:\/\/beonemedaffairs.com\/us\/publication\/tislelizumab-versus-sorafenib-in-first-line-treatment-of-unresectable-hepatocellular-carcinoma-impact-on-health-related-quality-of-life-in-rationale-301-study\/","title":{"rendered":"Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study\u00a0"},"content":{"rendered":"","protected":false},"template":"","post-tag":[],"class_list":["post-6685","publication","type-publication","status-publish","hentry","disease_state-hepatocellular-carcinoma","molecule-tislelizumab"],"acf":[],"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication\/6685","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/publication"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=6685"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=6685"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}